Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial), COPD Journal of Chronic Obstructive Pulmonary Disease, September 2018, Taylor & Francis,
DOI: 10.1080/15412555.2018.1481022.
You can read the full text:
Contributors
The following have contributed to this page
